Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + tremelimumab + paclitaxel
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen of three drugs used in oncology clinical trials: - **Durvalumab** is a human monoclonal antibody that targets programmed cell death ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 to promote antitumor immune responses by cytotoxic T cells. - **Tremelimumab** is a human monoclonal antibody targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), enhancing immune activation against tumor cells. - **Paclitaxel** is a small molecule chemotherapeutic agent that stabilizes microtubules and inhibits cell division. The combination has been studied in advanced cancers such as biliary tract carcinoma and metastatic gastric cancer after failure of platinum-based chemotherapy. The rationale for combining these agents is to enhance the immune-mediated attack on tumors while leveraging the cytotoxic effects of paclitaxel. However, safety concerns have arisen regarding increased risk of severe anaphylactic reactions when all three are combined[5][8].
- Brand names
- Abraxane
- Other names
- durvalumab + tremelimumab + paclitaxel
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)TUBA (Tubulin alpha/beta dimer)
Beyond the preview
Go deeper on durvalumab + tremelimumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + tremelimumab + paclitaxel.